< Back to latest news & events

Event

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

September 2025

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025.

Session Details

  • Topic: AI and Intellectual Property Rights
  • Date & Time: 15 September 2025, 07:30–08:30
  • Location: G412–G413, AIPPI World Congress
  • Moderator: Sofie McPherson, HGF
  • Speakers:

This engaging discussion will explore the impact of generative AI and how it is reshaping design and patent law.

The first segment focuses on design rights, examining whether AI-generated outputs—such as product shapes, logos, and packaging—can be protected under existing frameworks, and who, if anyone, owns these rights. Panelists will consider whether current laws requiring human authorship remain fit for purpose, or if a new legal category is needed to address AI-led creation.

The discussion will then turn to enforcement challenges, including aesthetic dilution, consumer confusion, and the strain on IP owners caused by AI’s ability to produce “lookalike” designs at scale. In the second segment, the conversation shifts to AI-generated content as potential prior art in patent and design law, and whether traditional standards of novelty and non-obviousness are being undermined. Questions will explore how different jurisdictions are responding, whether machine-generated content can or should be considered valid prior art, and whether disclosure obligations or new registries are needed.

The session will conclude with forward-looking reflections on how legislation, regulation, and global alignment may need to evolve to keep pace with AI’s growing influence on the IP landscape.

Click the button below to find out more.

 

Latest updates

Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article